Physician profile
Andreas Kaden
NPI 1578724852
$3,159.36
in general payments reported to CMS, 2019-2025
13 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $52.32 · 2021: $209 · 2022: $123 · 2023: $366 · 2024: $695 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $824.35 | 2019 | |
| Medtronic, INC. | $523.25 | 2021-2025 | Sinuva, Propel, Straightshot |
| Aerin Medical INC. | $423.73 | 2023-2024 | |
| Cochlear Americas | $404.22 | 2019-2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Acclarent, INC | $316.92 | 2019 | |
| Inspire Medical Systems, INC. | $206.09 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $170.66 | 2025 | Dupixent |
| Alk-Abello, INC | $165.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.35 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $25.91 | 2025 | |
| Phadia US INC. | $14.86 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $14.27 | 2023 | |
| Genzyme Corporation | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Kaden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.